biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > (TSXV:BTI.V; OTCQB:BIOAF): 4th Quarter/YE Statements

<< Previous

Bullboard Posts

Next >>

Comment by MineDiggeron Jun 15, 2022 9:40am

126 Views

Post# 34757707

RE:RE:(TSXV:BTI.V; OTCQB:BIOAF): 4th Quarter/YE Statements

ps: reflecting on “two contract dispute matters", maybe one is re jd, so just one fall-out with partners. Or another disgruntled employee perhaps.

And so the low gets lower (.17 traded at open, all of 1k! $11k now bid at .18).

<< Previous

Bullboard Posts

Next >>

Barrick Gold employees detained in Mali amid ongoing dispute